Nimacimab: Designed to Offer Distinct Capabilities

Date published: June 20, 2025 7:00 pm PDT

A review of Skye’s highly peripherally-restricted CB1 inhibitor and its advantages relative to the incretin class of anti-obesity drugs and small-molecule CB1 inhibitors, with recent preclinical data.